



EvaluateMedTech®

World Preview 2017, Outlook to 2022

Executive Summary

6th Edition – September 2017

 Evaluate®

Analysis Highlights

- Worldwide medtech sales forecast to reach \$522bn by 2022
 - Worldwide prescription drug market only forecast to grow at a marginally faster rate than the medtech market, with a CAGR of 5.2% between 2016 and 2022, versus 5.1% for medtech
-
- Total value of MedTech M&A deals rises by a massive 178% in H1 2017 despite drop in deal count
 - Abbott's acquisition of St. Jude results in it becoming the second largest cardiology company
 - Medtronic remains the largest medtech company in 2016 with sales of almost \$30bn
 - ...and Medtronic will remain at the top in 2022 with sales forecast to reach \$37.7bn; Abbott to jump to third place
 - Global medtech R&D spend set to grow by 3.7% (CAGR) to \$33.5bn by 2022
 - Medtronic top medtech R&D spender in 2022; Abbott to knock Johnson & Johnson off second place spot
 - In vitro diagnostics is expected to remain the largest medtech segment in 2022 with annual sales of \$70bn; Roche remains top player with expected sales of \$12.8bn in 2022
 - Diagnostic imaging sales forecast to reach \$48bn in 2022; Siemens, General Electric and Philips dominate the market
 - Johnson & Johnson continues to lead the orthopedic Market in 2022
 - Approval rate for innovative devices increases in the first eight months of 2017; cardiology outperforms other areas
 - Following the 10-year high in 2015, number of first-time PMAs and HDEs down 22% in 2016
 - Total value of MedTech venture financing deals rises 56% in H1 2017 despite the number of deals falling by 11%
 - Total value of MedTech IPOs continues to fall in H1 2017 to \$122m

Worldwide Medtech Sales by Device Area in 2022


Worldwide medtech sales forecast to grow by 5.1% (CAGR) to \$522bn by 2022; in vitro diagnostics retains its number one spot in 2022.

Evaluate consensus forecasts find that the value of the worldwide medtech market will reach \$521.9bn by 2022, growing at a rate of 5.1% per year (CAGR) between 2016 and 2022.

In vitro diagnostics is expected to remain the largest segment in 2022 with annual sales of \$69.6bn, well ahead of second placed Cardiology. Neurology is again forecast to be the fastest-growing device area, with sales expected to rise to \$11.6bn in 2022, representing 7.8% market growth per year (CAGR) between 2016 and 2022.

Analysis on Top 10 Device Areas in 2022, Market Share & Sales Growth (2016-2022)

Source: Evaluate, September 2017



Worldwide Medtech Sales by EvaluateMedTech® Device Area: Top 15 Categories & Total Market (2016 & 2022)

Source: Evaluate, September 2017

Rank	Device Area	WW Sales (\$bn)		CAGR % Growth	WW Market Share			Rank Chg. (+/-)
		2016	2022		2016	2022	Chg. (+/-)	
1.	In Vitro Diagnostics (IVD)	49.4	69.6	+5.9%	12.8%	13.3%	+0.6pp	-
2.	Cardiology	44.6	62.3	+5.7%	11.5%	11.9%	+0.4pp	-
3.	Diagnostic Imaging	39.2	48.0	+3.4%	10.1%	9.2%	-1.0pp	-
4.	Orthopedics	35.0	44.4	+4.0%	9.0%	8.5%	-0.5pp	-
5.	Ophthalmics	26.0	35.4	+5.3%	6.7%	6.8%	+0.1pp	-
6.	General & Plastic Surgery	20.4	27.8	+5.3%	5.3%	5.3%	+0.0pp	-
7.	Endoscopy	17.8	25.7	+6.4%	4.6%	4.9%	+0.3pp	+1
8.	Drug Delivery	18.6	24.6	+4.8%	4.8%	4.7%	-0.1pp	-1
9.	Dental	12.8	17.8	+5.6%	3.3%	3.4%	+0.1pp	+1
10.	Wound Management	13.0	16.9	+4.5%	3.4%	3.2%	-0.1pp	-1
11.	Diabetic Care	11.0	16.2	+6.6%	2.9%	3.1%	+0.2pp	+1
12.	Nephrology	11.1	14.6	+4.6%	2.9%	2.8%	-0.1pp	-1
13.	General Hospital & Healthcare Supply	11.0	12.8	+2.5%	2.8%	2.4%	-0.4pp	-
14.	Neurology	7.4	11.6	+7.8%	1.9%	2.2%	+0.3pp	+3
15.	Ear, Nose & Throat (ENT)	8.0	11.1	+5.5%	2.1%	2.1%	+0.0pp	-1
	Top 15	325.4	438.6	+5.1%	84.1%	84.0%	-0.1pp	
	Other	61.4	83.3	+5.2%	15.9%	16.0%	+0.1pp	
	Total WW Medtech Sales	386.8	521.9	+5.1%	100.0%	100.0%		

Note: Analysis is based on the top 300 medtech companies. Sales in 2016 based on company reported data. Sales forecasts to 2022 based on a consensus of leading equity analysts' estimates for segmental sales.

Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support.

EvaluatePharma[®] delivers exclusive consensus sales forecasts and trusted commercial insight into biotech and pharmaceutical performance.

 [@EvaluatePharma](https://twitter.com/EvaluatePharma)

EvaluateMedTech[®] sets a new standard in commercial analysis and consensus forecasts of the global medical device and diagnostic industry.

 [@EvaluateMedTech](https://twitter.com/EvaluateMedTech)

EvaluateClinical Trials[®] delivers unique clinical trial intelligence expertly curated to efficiently analyse the global clinical trial landscape.

 [@EPClinicalTrial](https://twitter.com/EPClinicalTrial)

EP Vantage an award winning editorial team, provides daily commentary and analysis with fresh perspectives and insight into current and future industry trends.

 [@EPVantage](https://twitter.com/EPVantage)

Evaluate Custom Services provides customised solutions to help you access, analyse and manage the information you need to support effective decision-making.

The Evaluate services enable the life science community to make sound business decisions about value and opportunity.

www.evaluate.com

Evaluate Headquarters

Evaluate Ltd.
11-29 Fashion Street
London E1 6PX
United Kingdom
T +44 (0)20 7377 0800
F +44 (0)20 7539 1801

Evaluate Americas

EvaluatePharma USA Inc.
15 Broad Street, Suite 401
Boston, MA 02109
USA
T +1 617 573 9450
F +1 617 573 9542

Evaluate APAC

Evaluate Japan KK
Akasaka Garden City 4F
4-15-1 Akasaka, Minato-ku
Tokyo 107-0052
Japan
T +81 (0)80 1164 4754